Top 20 Generic Companies of 2026 

Shots:   Sandoz, Sun Pharma, and Shanghai Fosun Pharma emerged as the leading generic pharmaceutical companies in 2026, with 2025 revenues of $11.08B, $6.55B, and $5.92B, respectively. Strong demand for biosimilars, continued portfolio expansion, new product launches, and broader access to affordable medicines supported growth across the leading companies The global generics landscape continues to evolve as pharmaceutical companies expand beyond traditional small-molecule medicines into complex generics, biosimilars, injectables, inhalation products, and GLP-1 therapies. Increasing competition, new product launches, licensing partnerships, manufacturing expansion, and the growing adoption of biosimilars are reshaping the competitive landscape and creating new opportunities for affordable healthcare The report ranks the Top 20 Generic Pharmaceutical Companies of 2026 based on their generic-related revenue reported for fiscal year 2025, with revenues converted to USD. It highlights the companies’ key generic and biosimilar products, year-over-year revenue performance, factors influencing growth or decline, and the latest product launches, regulatory approvals, partnerships, licensing agreements, and commercialization deals shaping the global generic medicines market   20. Alkem  Generic Segment Revenue: $1.64B   Founded Year: 1973   Market Cap: $6.67B   Total Employees: 19,300   Headquarters: Maharashtra, India   Stock Exchange: NSE  Alkem has established itself as a major Indian pharmaceutical company with a strong branded generics franchise and an expanding international business. Its portfolio covers anti-infective, gastroenterology, cardiovascular, diabetes and other high-volume therapeutic areas  Revenue increased from $1.49B in 2024 to $1.64B in 2025, representing 10.1% growth. Stronger domestic pharmaceutical performance and continued portfolio expansion helped drive the improvement  In June 2026, Alkem became the first company in India to launch semaglutide in single shot prefilled syringes, following its March launch of semaglutide injection. The new presentation starts at ₹350, giving the company another entry point into India’s rapidly developing GLP1 market 19. Towa Pharmaceutical Co  Generic Segment Revenue: $1.72B   Founded Year: 1951   Market Cap: $1.22B   Total Employees: 4,900   Headquarters: Osaka, Japan  Stock Exchange: TYO  Towa is deeply rooted in Japan’s generic medicines market and has increasingly expanded its international footprint. Its strategy combines a large domestic generic portfolio with overseas commercialization and manufacturing partnerships.  Revenue increased from $1.60B in 2024 to $1.72B in 2025, a 7.5% increase, reflecting continued growth in its core generic business and international operations.  In January 2026, Towa and Otsuka Pharmaceutical announced a strategic collaboration covering product manufacturing, generic development using Otsuka licenses and mutual backup manufacturing. The agreement strengthens Towa’s access to products and manufacturing opportunities while deepening its relationship with a major Japanese pharmaceutical group  18. Amneal  Generic Segment Revenue: $1.74B   Founded Year: 2002   Market Cap: $6.02B   Total Employees: 8,700   Headquarters: New Jersey, United States  Stock Exchange: NASDAQ  Amneal Pharmaceuticals is a US based pharmaceutical company focused on generics and speciality medicines, with a broad portfolio spanning complex generics, injectables, biosimilars and other affordable treatments.  Revenue increased from $1.68B in 2024 to $1.74B in 2025, a 3.6% rise, driven by new product launches. Its generic portfolio includes complex products across areas such as ophthalmology, injectables, respiratory and central nervous system therapies.  In July 2026, Amneal received US FDA approval for additional iohexol injection strengths and vial presentations, expanding its generic contrast injection portfolio and giving it coverage across most of the US iohexol market.  17. Stada  Generic Segment Revenue: $1.8B   Founded Year: 1895   Market Cap: N/A  Total Employees: 23,000   Headquarters: Bad Vilbel, Germany   Stock Exchange: N/A  STADA operates across three complementary pillars – generics, specialty pharmaceuticals and consumer healthcare with generics forming a core part of its European healthcare platform. Its partnership-led model allows it to broaden its portfolio without relying entirely on internal development Revenue increased from $1.72B in 2024 to $1.80B in 2025, up 4.7%. Growth was supported by the company’s broad product portfolio and continued expansion across European markets In March 2026, STADA signed a major agreement with CuraTeQ Biologics to market and distribute pegfilgrastim and filgrastim biosimilars across key European markets, adding two products to its already substantial biosimilar portfolio.  16. Glenmark Pharmaceuticals  Generic Segment Revenue: $1.86B   Founded Year: 1977   Market Cap: $6.86B   Total Employees: 15,800   Headquarters: Maharashtra, India  Stock Exchange: NSE  Glenmark combines a large generic portfolio with specialty and innovative medicines, with the US remaining an important market for its complex generic strategy. Injectable and respiratory products are increasingly prominent in its international portfolio Revenue increased from $1.63B in 2024 to $1.86B in 2025, representing 14.1% growth. The improvement reflects stronger performance across its businesses and continued addition of differentiated products, particularly in regulated markets In March 2026, Glenmark launched several US generic products, including an authorized generic of milnacipran hydrochloride tablets, potassium phosphates injection and sodium phosphates injection. These launches reinforce its focus on complex and injectable generics  15. Krka  Generic Segment Revenue: $2.19B   Founded Year: 1954  Market Cap: $26.2B   Total Employees: 23,000   Headquarters: Novo mesto, Slovenia   Stock Exchange: WSE  Krka has built its business around high-quality generic medicines, with a particularly broad presence across Europe and emerging markets. Its portfolio covers chronic diseases, including cardiovascular, gastrointestinal, CNS and metabolic conditions, alongside animal-health products Revenue increased from $1.81B in 2024 to $2.19B in 2025, a strong 21.0% increase, reflecting increased sales across both major business segments. Krka’s broad geographic reach and continued product additions have supported this momentum In July 2026, Krka reported that it had expanded its portfolio with six prescription pharmaceuticals and one companion-animal product during the first half of the year. The company also reported estimated H1 revenue of €1.119B, up 7%  14. Aspen  Generic Segment Revenue: $2.55B   Founded Year: 1850  Market Cap: $3.92B   Total Employees: 9,300   Headquarters: South Africa, Durban   Stock Exchange: JSE  Aspen Pharmacare is one of Africa’s largest pharmaceutical manufacturers, with a global footprint spanning generics, branded medicines, sterile products and active pharmaceutical ingredients. Its manufacturing base gives it particular strength in supplying essential medicines at scale Revenue rose from $2.42B in 2024 to $2.55B in 2025, a 5.4% increase, supported by continued demand across its pharmaceutical portfolio and geographic markets In July 2026, Aspen received Canadian approval for Aspen-Semaglutide, a generic version of Ozempic, opening an important opportunity in the rapidly expanding GLP-1 market and further broadening its generic portfolio  13. Celltrion  Generic Segment Revenue: $2.88B   Founded Year: 2002   Market Cap: $32.94B   Total Employees: 2,700   Headquarters: Incheon, South Korea  Stock Exchange: KRX  Celltrion has made biosimilars the centrepiece of its global pharmaceutical strategy, building an integrated model covering development, manufacturing and commercialization. Its portfolio spans oncology, immunology and other major biologic therapies Revenue increased from $2.41B in 2024 to $2.88B in 2025, a substantial 19.5% increase, driven by an overall sales increase and strong uptake of newer biosimilar products. Celltrion reported record 2025 revenue, with biopharmaceutical sales growing 24% In March 2026, Celltrion launched the liquid formulation of Remsima (infliximab) in Europe, adding a differentiated formulation to its biosimilar portfolio. Later that month, it also made AVTOZMA SC (tocilizumab) commercially available in the US  12. Lupin  Generic Segment Revenue: $2.94B   Founded Year: 1968   Market Cap: $10.69B   Total Employees: 26,000   Headquarters: Mumbai, India  Stock Exchange: NSE  Lupin has evolved from a strong India-focused pharmaceutical player into a global company with significant capabilities in complex generics, inhalation products, injectables, APIs and biotechnology. The US remains an important market for its differentiated generic strategy Revenue grew from $2.59B in 2024 to $2.94B in 2025, a 13.5% increase. The improvement reflects stronger product launches and geographic diversification, with complex generics and specialty products helping Lupin reduce reliance on traditional commodity generics In March 2026, Lupin received tentative US FDA approval for Sugammadex Injection, a generic equivalent of Bridion, adding another complex injectable to its pipeline. Lupin also reported first-to-file launches of dapagliflozin and tolvaptan during FY26 11. Zydus  Generic Segment Revenue: $2.95B   Founded Year: 1952  Market Cap: $11.84B   Total Employees: 30,000   Headquarters: Ahmedabad, India  Stock Exchange: NSE  Zydus combines a large generic medicines franchise with biosimilars, vaccines and innovative therapies. Its international generics business, particularly in the US, remains an important part of its global pharmaceutical platform Revenue increased from $2.64B in 2024 to $2.95B in 2025, a robust 11.7% increase. The growth reflects continued expansion across its pharmaceutical businesses and an increasing contribution from differentiated and higher-value products alongside its established generic portfolio In 2026, Zydus continued expanding its partnership and licensing activity around specialty products, while its US business maintained momentum through new generic approvals. For the report, I would position this as evidence of Zydus moving beyond volume-driven generics toward more differentiated products  10. Cipla  Generic Segment Revenue: $3.26B   Founded Year: 1935   Market Cap: $12.26B   Total Employees: 31,400   Headquarters: Mumbai, India   Stock Exchange: NSE  Cipla has built a distinctive generic franchise around respiratory medicines, supported by a growing portfolio of complex inhaled products, injectables and other difficult-to-manufacture formulations. Its India, emerging-market and North American businesses give the company a broad geographic footprint Revenue rose from $3.15B in 2024 to $3.26B in 2025, a 3.5% increase. Growth was supported by expansion across its key markets, while the company continued to invest in complex generics and respiratory products to improve the quality of its portfolio In April 2026, Cipla received US FDA approval for the first AB-rated generic of Ventolin HFA, strengthening its US respiratory franchise. The product is manufactured at Cipla’s new US inhalation facility in Massachusetts  9. Hikma  Generic Segment Revenue: $3.34B   Founded Year: 1978   Market Cap: $4.61B   Total Employees: 31,400   Headquarters: London, United Kingdom   Stock Exchange: LON  Hikma Pharmaceuticals is a global pharmaceutical company focused on affordable generic, specialty and branded medicines, with a strong position in sterile injectable generics, particularly in the US and MENA markets Revenue increased from $3.15B in 2024 to $3.34B in 2025, a 6.0% rise, driven by overall sales growth. Its generic portfolio includes a broad range of oral, injectable and complex medicines, with injectables remaining a key strength In April 2026, Hikma launched authorized generics of tapentadol in the US and signed a licensing and co-development deal for device technology supporting its generic Ellipta program. In July 2026, it further expanded its injectable portfolio with Sugammadex Injection prefilled syringes 8. Teva  Generic Segment Revenue: $3.65B   Founded Year: 1944   Market Cap: $42.51B   Total Employees: 32,000   Headquarters: Tel Aviv, Israel  Stock Exchange: NYSE  Teva is one of the world’s best-known generic pharmaceutical companies, with a vast portfolio of conventional and complex generics complemented by biosimilars and innovative medicines. Its scale gives it a particularly strong position in the US generic market Revenue increased from $3.59B in 2024 to $3.65B in 2025, up 1.7% on the figures provided. Within its US business, generic products including biosimilars generated $3.657B in 2025, up 2% from $3.599B in 2024, with growth supported by biosimilars and new product launches In June 2026, Teva launched AHZANTIVE (aflibercept), a biosimilar to Eylea, in Europe, expanding its ophthalmology offering and strengthening its European biosimilar portfolio  7. Aurobindo Pharma  Generic Segment Revenue: $3.69B   Founded Year: 1986   Market Cap: $9.8B   Total Employees: 29.200   Headquarters: Hyderabad, India   Stock Exchange: NSE  Aurobindo Pharma has developed a broad generic platform spanning oral solids, injectables, specialty products and APIs, with a particularly important presence in the US and other regulated markets. Its vertically integrated manufacturing model supports a large and diverse product pipeline Revenue edged up from $3.61B in 2024 to $3.69B in 2025, a 2.2% increase. The relatively modest growth reflects a mature generic business where product launches, geographic expansion and portfolio mix remain important counterbalances to pricing pressure In 2026, Aurobindo’s generic and biosimilar strategy received another boost through its global licensing activity, while its subsidiary CuraTeQ became the partner behind STADA’s European commercialization deal for two neutropenia biosimilars pegfilgrastim and filgrastim in March 2026  6. Dr. Reddy’s   Generic Segment Revenue: $3.84B   Founded Year: 1984   Market Cap: $10.48B   Total Employees: 27,500   Headquarters: Hyderabad, India  Stock Exchange: NSE  Dr. Reddy’s Laboratories has built its global identity around affordable medicines, with generics supported by extensive API capabilities and a growing presence in biosimilars and complex products. Its portfolio spans oncology, cardiovascular, diabetes, gastrointestinal and other high-demand therapies Revenue grew from $3.51B in 2024 to $3.84B in 2025, up 9.4%. The company continued to broaden its generic portfolio across North America, Europe and emerging markets; in Q3 FY26 alone, it added new products across all three major geographic businesses In April 2026, Dr. Reddy’s received marketing authorization for generic semaglutide injection in Canada, extending its presence in the emerging GLP-1 generic market  5. Viatris  Generic Segment Revenue: $5.06B   Founded Year: 2020   Market Cap: $18.42B   Total Employees: 30,000   Headquarters: Pennsylvania, United States  Stock Exchange: NASDAQ  Viatris was created around the idea of combining global scale with access-focused medicines, and today operates a broad portfolio of generics, complex generics, biosimilars and established brands across developed and emerging markets Revenue declined from $5.49B in 2024 to $5.06B in 2025, a 7.8% decrease, reflecting lower sales in developed markets and the Japan/Australia/New Zealand region. The decline indicates the pressure that mature generic markets can place on pricing and volumes In August 2026, Viatris agreed to sell the global rights to Tyrvaya to Harrow for $30M upfront plus up to $70M in commercial milestone payments. The transaction reflects Viatris’ continued portfolio optimization and focus on its core businesses  4. Fresenius Kabi  Generic Segment Revenue: $5.41B   Founded Year: 1999   Market Cap: $30.72B   Total Employees: 178,000   Headquarters: Bad Homburg, Germany   Stock Exchange: ETR  Fresenius Kabi brings a strong hospital-focused portfolio to the generic medicines landscape, particularly through injectable drugs, infusion therapies, clinical nutrition and biosimilars. Its strength lies in complex products that are closely integrated with hospital care Revenue climbed sharply from $3.99B in 2024 to $5.41B in 2025, a 35.6% increase, driven primarily by higher sales in the biopharma segment. Biosimilars and injectable medicines therefore remain important components of its expanding pharmaceutical portfolio In August 2026, Fresenius Kabi announced US FDA approval of a rituximab biosimilar developed by Dr. Reddy’s, with Fresenius Kabi holding US commercialization rights. The agreement strengthens its position in oncology biosimilars  3. Shanghai Fosun Pharma  Generic Segment Revenue: $5.92B   Founded Year: 1978   Market Cap: $7.33B   Total Employees: 40,600   Headquarters: Shanghai, China   Stock Exchange: SHA  Fosun Pharma combines pharmaceutical manufacturing with innovation, healthcare and global commercialization capabilities. Its portfolio spans generics, innovative medicines, biosimilars and specialty products, giving it a broader profile than a conventional generic manufacturer Revenue increased from $5.60B in 2024 to $5.92B in 2025, representing 5.7% growth. The company benefited from overall business expansion, while its international operations and growing innovative-product portfolio provided additional momentum. In 2025, Fosun also reported FDA and EU approvals for its denosumab biosimilars In May 2026, Fosun Pharma and AriBio signed an exclusive global option agreement covering development, manufacturing and commercialization of AR1001. Although focused on an innovative Alzheimer’s candidate rather than a conventional generic, the deal highlights Fosun’s broader licensing and global commercialization strategy 2. Sun Pharma  Generic Segment Revenue: $6.55B   Founded Year: 1983   Market Cap: $48.32B   Total Employees: 47,000   Headquarters: Mumbai, India   Stock Exchange: NSE  From its beginnings in India, Sun Pharma has grown into a global pharmaceutical company with businesses spanning generics, specialty medicines and active pharmaceutical ingredients. Its generic franchise remains particularly strong across India, emerging markets and regulated markets Revenue rose from $6.26B in 2024 to $6.55B in 2025, up 4.6%. Its generic portfolio covers areas such as cardiovascular, gastroenterology, anti-infectives and dermatology, while the company is increasingly adding complex generics and differentiated products to its offering In July 2026, Sun Pharma received approval to manufacture and market generic semaglutide in South Africa, marking another step in its expansion into the fast-growing GLP-1 segment  1. Sandoz  Generic Segment Revenue: $11.08B   Founded Year: 1886   Market Cap: $39.13B   Total Employees: 20,000   Headquarters: Basel, Switzerland   Stock Exchange: SWX  Sandoz is one of the world’s largest dedicated generics and biosimilars companies, with a portfolio spanning affordable small-molecule medicines and biologics across major therapeutic areas. Its scale is particularly notable in biosimilars, where it has built a broad international presence Revenue increased from $10.35B in 2024 to $11.08B in 2025, a 7.1% increase, with higher biosimilar revenue providing the key lift. The company’s generic portfolio includes products across anti-infectives, cardiovascular, CNS, ophthalmology and other major therapeutic categories, while biosimilars have become an increasingly important growth engine In June 2026, Sandoz advanced its GLP-1 strategy after the US FDA accepted applications for its in-house-developed generic tirzepatide products, adding another potentially significant product opportunity to its pipeline Criteria:  The report is based on generic pharmaceutical revenues reported during fiscal year 2025, covering conventional generics, complex generics, biosimilars, and other affordable medicine portfolios to provide a comprehensive ranking of the world’s leading generic pharmaceutical companies For companies with non-December fiscal year endings, revenue has been aligned to the January–December 2025 period using quarterly and annual financial filings. Where generic-specific revenues were not separately disclosed, the relevant pharmaceutical or generics segment figures were used based on the company’s reported business structure and publicly available financial disclosures Revenues reported in different currencies have been converted into US dollars using exchange rates as of 31 December 2025 to ensure consistency and comparability across all companies in the ranking   Sources:   Company Websites    Press Releases    Annual Reports      Quarterly Reports     Google Finance OANDA         Related Post: Top 20 Generic Pharma Companies of 2025   The post Top 20 Generic Companies of 2026  appeared first on PharmaShots.